Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension


AYPAR E. , ALEHAN D. , KARAGÖZ T. , AYKAN H. H. , ERTUĞRUL İ.

CARDIOLOGY IN THE YOUNG, vol.28, no.4, pp.542-547, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.1017/s1047951117002542
  • Title of Journal : CARDIOLOGY IN THE YOUNG
  • Page Numbers: pp.542-547

Abstract

Background Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term event-driven study.